article thumbnail

Searching for answers in rare epilepsy

pharmaphorum

Charlie has spent more than 26 years working on the human genome – 22 of which were spent at the Wellcome Sanger Institute, helping to assemble the human genome and trying to understand the function of the genes contained within it. Shortly after that, she started making jackknife movements.

Genome 85
article thumbnail

Searching for answers in rare epilepsy

pharmaphorum

Charlie has spent more than 26 years working on the human genome – 22 of which were spent at the Wellcome Sanger Institute, helping to assemble the human genome and trying to understand the function of the genes contained within it. Shortly after that, she started making jackknife movements.

Genome 70
article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

Secondary and exploratory endpoints in the study will evaluate changes in other disease measures, including seizures and additional non-seizure comorbidities. Participants continue to receive their usual care, and will be observed by a team of doctors and nurses over time for up to two years. 4, 2020 14:57 UTC. BEDFORD, Mass.–(